Dana Pizzuti - Feb 20, 2025 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Med and Dev Officer
Signature
Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Feb 20, 2025
Transactions value $
$0
Form type
4
Date filed
2/24/2025, 04:30 PM
Previous filing
Feb 5, 2025
Next filing
Mar 21, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Award $0 +43K +135.44% $0.00 74.7K Feb 20, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (Right to Buy) Award $0 +65K $0.00 65K Feb 20, 2025 Common Stock 65K $36.86 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2026.
F2 The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 20, 2025.